SMAD4 and metastatic colorectal cancer: Similar results revealed that mutations in BRAF and SMAD4 were significantly correlated with the overall survival (Supplementary Figure S2; BRAF: p = 4.47 × 10−6 and SMAD4: p = 0.048) of patients with metastatic colorectal cancer.